Boehringer Ingelheim and Eli Lilly’s heart failure drug molecule touched an important milestone in reducing the risk of cardiovascular death or hospitalization in heart failure patients with and without diabetes in phase III trials.**
At the present clinical scenario, Jardiance is indicated adult patients with type 2 diabetes, as well as minimizing the risk of cardiovascular-related deaths in adults suffering from type 2 diabetes and having known cardiovascular disease.
Heart failure is the most common cause of hospital admission in patient over 65 years in the UK and Ireland as well as in the US and Europe.
The EMPEROR-Reduced trial evaluated SGLT2 inhibitor empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF). The drug showed promising results as it met the primary endpoint in the reduction of death and hospitalization in patients with type 2 diabetes mellitus along with the cardiovascular disease. The safety and efficacy portfolio is similar the safety profile of empagliflozin.
Beside the EMPEROR-Reduced trial, both companies are working on the role of Jardiance in the treatment and management of heart failure patients having preserved ejection fraction (HFpEF).
Till date the companies do not reveal full trial results, but in the near future it will help the patients in the competitive market.
Comprehensive results of the trial will be presented at the European Social of Cardiology (ESC) congress 2020 on August 29, 2020.
Dr Milton Packer, Chair of the Executive Committee for the EMPEROR Program and Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center in Dallas, Texas, US, said: “The results of the EMPEROR-Reduced trial indicate that SGLT2 inhibitors have the potential to become new standard of care for this disease, which will be a meaningful addition to the currently established treatments.”
Jardiance, an SGLT2 blocker, is expected to produce a positive impact in the vast and competitive diabetes and cardiovascular protection clinical entity.